Dataset opportunity
Sterlingpharmasolutions — API-Accessible Dataset Opportunity
Large api-accessible dataset held by Sterlingpharmasolutions, usable for RAG and Fine Tuning.
Score
71.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
82%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Pharma Manufacturing market was valued at $1.26 billion in 2025, with a projected CAGR of 29.45% (2026-2034).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
API-Accessible Dataset
Modality
Multimodal
Sector
healthcare
Volume
Large
Freshness
Periodic
Rarity
Medium
Accessibility
Partial
Legal
Mixed ownership — restricted
Buyer persona
LLM application teams & enterprise search vendors
Sterling Pharma Solutions holds a multimodal, API-Accessible Dataset derived from its contract development and manufacturing operations. It contains extensive industrial_data, including process optimization logs and manufacturing records, alongside crucial regulatory documentation, business records, and a proprietary knowledge_base. This rich combination of structured and unstructured data is highly suitable for developing and grounding RAG applications to navigate complex pharmaceutical manufacturing, quality, and compliance inquiries.
The value of this data is underscored by the AI in Pharma Manufacturing market, which was valued at $1.26 billion in 2025 and is projected to grow at a 29.45% CAGR. Despite access complexities such as split data ownership (client IP vs. Sterling's process data), strict GMP/FDA compliance, and client CDAs, the dataset's rarity and depth offer a significant competitive advantage. The high-integrity data is essential for AI buyers looking to innovate within this rapidly expanding, high-value sector. ⚠ Diligence (valuable data, access to negotiate): Data ownership is split: clients own molecule IP while Sterling owns process optimization and manufacturing logs.; Strict regulatory compliance (GMP/FDA) requires high data integrity and controlled access.; Confidentiality Disclosure Agreements (CDAs) with global pharma clients limit data portability. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves the holder possesses a deep, multimodal dataset covering the entire API lifecycle, from early development to scaled manufacturing. The data includes proprietary process-chemistry workflows, decades of process-safety records, and detailed analytical methods. For AI application teams and enterprise search vendors, this is a prime asset for building specialized RAG systems that can answer complex queries about pharmaceutical contract development and manufacturing (CDMO) operations. In a market where AI in pharma manufacturing is projected to grow at nearly 30% annually, this dataset offers a significant competitive advantage by providing ground-truth operational data.
See dimension details ↓- Dataset Specificity78
dominant 'api', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume100
12 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value64
fit for RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is exceptionally strong, driven by the high-growth AI in Pharma Manufacturing market which is expanding at a 29.45% CAGR.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility64
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility68
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength100
6 evidence types, 12 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License32
ownership=mixed, licensing=restricted
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ good target — Sterling Pharma Solutions is a good target as it's a large, operational CDMO generating proprietary data from its core business of API development and manufacturing, which it does not appear to sell as a separate product. Issues: The company is larger than a typical SME, with employee counts ranging from over 1,000 to 1,350, which may affect its classification as a target.; The term 'API' in the source description 'API-Accessible Dataset' likely refers to 'Active Pharmaceutical Ingredient', the company's core business, not 'Applica
- Deep Qualification90
⚠ needs review — Sterling is a CDMO that generates high-value process and manufacturing data as a byproduct of its core business, but strict client confidentiality and IP agreements make data resale highly restricted. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
API access
Publicly accessible content details the company's core services in API manufacturing and ADC development, providing foundational business context and terminology for LLM training.
Industrial data
Proprietary industrial data from process-chemistry workflows and a 30-year process-safety program offers invaluable material and time-series data for building predictive models in pharmaceutical manufacturing.
Downloads / exports
The company offers downloadable corporate resources, such as facility specifications in a tabular format, which provide structured data points for knowledge graph construction.
Knowledge base / docs
A proprietary knowledge base details complex analytical services and methods, offering high-value technical text for training models on pharmaceutical quality and compliance.
business_records
Internal business records, including electronic lab notebooks and process sheets, represent a deep well of structured data on pharmaceutical development and quality control.
Regulatory records
Specialized regulatory documentation on Quality by Design (QbD) and CMC support provides essential text for training AI on the complex requirements of new drug application filings.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Sterlingpharmasolutions API-Accessible — a Large api-accessible dataset (Multimodal modality) in the healthcare domain. Primary AI use-case: RAG. Market signal: Global AI in Pharma Manufacturing market was valued at $1.26 billion in 2025, with a projected CAGR of 29.45% (2026-2034).. Investment score 71.4/100 (confidence 0.82). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Wallabymedical — Medical Imaging Dataset Opportunity
View opportunity →otherCreativesalmon — Regulatory Records Dataset Opportunity
View opportunity →otherLochduart — Regulatory Records Dataset Opportunity
View opportunity →